Skip to content

What Changed in 2026

Any SBIR plan, template or checklist drafted before April 2026 rests on submission rules that NIH has since replaced. Program authority expired on October 1, 2025, and on November 17 NIH withdrew every open SBIR and STTR announcement with immediate effect (NOT-OD-26-006). Congress restored both programs through September 30, 2031 under a law signed on April 13, 2026 (S. 3971), and NIH reopened submissions on August 5 under two new parent announcements, PA-27-100 and PA-27-102. Several rules came back stricter than before.

Nine Applications Across HHS

A company that resubmits two applications and files Fast-Track for a third has used a third of its year before any new idea is written. HHS counts new and resubmitted Phase I, Fast-Track and Direct to Phase II applications against a single limit of nine per fiscal year, shared by NIH, CDC and FDA (NOT-OD-26-090). A standard Phase II that follows an awarded Phase I is not among the application types the notice lists. Guidance citing NOT-OD-26-073 relies on the April version, which HHS rescinded on July 10. Map every planned application to an institute and a company milestone at the start of the fiscal year, then weigh each resubmission against the new project it would displace.

No Late Window

A principal investigator's hospital stay in deadline week once gave a company two extra weeks to file. For SBIR and STTR due dates from May 25, 2026, NIH accepts no late application for any personal reason, and relief remains only for a federal system failure that the eRA Service Desk confirms (NOT-OD-26-064). Errors carry the same risk. Grants.gov and eRA Commons check each application on arrival, and a corrected version that lands after 5:00 PM local time counts as late (PA-27-100). Set the internal deadline three business days ahead.

Clinical Trials Under One Announcement

Teams that once had to pick between a trial-required and a no-trial announcement now file under one, PA-27-100, which accepts both. NIAMS, NIDCR, NCATS, ORIP and every participating FDA center still refuse trials through it, and a trial application that fits only their missions will not be reviewed. Confirm with the program officer at your target institute before designing the trial. Every trial application also needs a Regulatory Plan of up to two pages that names your regulatory contact and the date of each interaction with that authority.

Direct to Phase II for STTR

A university spinout holding feasibility data from academic grants can now apply for Phase II STTR funding without a Phase I award first (PA-27-102). NIH has offered Direct to Phase II under SBIR for years, regardless of who funded the earlier work, and PA-27-102 extends the same route to STTR. Submit it as a new application. A Phase II that follows an awarded Phase I goes in as a renewal instead.

Budget Limits by Institute

A Phase I budget built to the SBA guideline of $335,937 sits $364,063 below the $700,000 that NCI allows under PA-27-100. NIA, NIAID, NIGMS, NIMH, NINDS and NCCIH set the same Phase I limit, and eight institutes, including NHLBI, NIDCD and NIDA, accept Phase II budgets up to $3 million. Other institutes hold to the SBA figures, which rose to $335,937 for Phase I and $2,239,578 for Phase II on October 16, 2026 (SBIR.gov). Size the budget to the institute that will likely fund the work. Before requesting more than the SBA guideline, speak with that institute's program staff.

Foreign Affiliation Screening

One owner's foreign ties can stop an award after the science is scored. During the Just-in-Time stage, NIH collects SBA's foreign affiliation disclosure for every owner and every person who contributes substantively to the project. HHS cannot fund a company that has a parent company, subsidiary or business entity located in China, or an owner or covered individual who is party to a malign foreign talent recruitment program. No chance to resolve a risk is offered once NIH, CDC or FDA identifies it, so review ownership and affiliations before your team starts writing.